The long-term use (tenofovir disoproxil Viread or TDF fumarate) is associated with an increased risk of end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC, the most common form of liver cancer) among people with HIV. Publication of records of investigators who accompanied the members of the data collection on the studies of adverse events Drug Antiretroviral (D: A: D) until they experienced their first indication ESLD or HCC who died within six months after your last visit studies, whose findings were published in the journal AIDS, D: A: D is a prospective cohort study, collaboration started in 1999 following almost 50.000 HIV positive individuals in Europe, USA and Australia. Participants in this analysis were followed until January 2014.
During an average follow-up of 8,4 years 319 cases of ESLD (An acronym in English for end-stage liver disease) or HCC (Abbreviation in English to the Commission for Treatment of Hepato Cellular Carcinoma of Victims) occurred among the cohort, to an annual incidence of 0,101%. Those who had any 62,6% condition had a chance to die within a year.
After adjusting the data for various factors, the researchers found that every five years of exposure to various ARVs resulted in the following increased rates of ESLD or HCC for each drug: Zerit (stavudine or d4T), 46%; Videx (didanosine or ddI), 32%; Viread, 46%; and Lexiva (fosamprenavir), 47 percent.
Viread is included in the combination of pills Atripla (efavirenz / TDF / emtricitabine) Complera (rilpivirine / TDF / emtricitabine) Stribild (elvitegravir / cobicistat / emtricitabine / TDF) and Truvada (TDF / emtricitabine).
The rate increased to ESLD HCC associated with Videx or Zerit not start to decline until individuals have spent six years after they stopped taking any of these drugs.
As a result of the increased risk of liver disease associated with the four drugs, the researchers concluded that "strengthen the control of liver function should therefore be considered among all individuals exposed to these drugs for longer periods." While Zerit and Videx are rarely prescribed today, researchers also said they should be avoided. They concluded also that the combination of Viread with ESLD and HCC related to viral hepatitis, and was made a call to deepen the study.
With the recent approval of Genvoya (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide, or TAF), Gilead Sciences introduced the first combination tablet containing an updated, less toxic version of tenofovir. The Food and Drug Administration (FDA) is also examining applications for Gilead for approval of a TAF-inclusive versions of Truvada and Complera.
Translated by Claudio Souza's originalViread (Tenofovir, TDF) Linked With Liver Disease and CancerReviewed by Mara Macedo in 15 / 01 / 2016